Precision BioSciences Newsroom

Precision BioSciences to Participate in Upcoming June Investor Conferences

Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene

BusinesswireMay 30 07:00 ET

Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B

TipRanksMay 30 06:29 ET

Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential

TipRanksMay 20 16:25 ET

Express News | Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

ReutersMay 17 07:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

BenzingaMay 16 13:36 ET

Precision BioSciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 395.87% HC Wainwright & Co. → $60 Reiterates Buy → Buy 04/30/2024 57.02% Guggenheim → $19 Initi

BenzingaMay 16 13:35 ET

Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)

TipRanksMay 15 12:10 ET

Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments

TipRanksMay 14 07:25 ET

Buy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong Financials

TipRanksMay 13 18:55 ET

Quarterly Results Takes Precision BioSciences Higher

RTTNewsMay 13 08:48 ET

Precision BioSciences Reports Profit From Cont. Ops. In Q1

RTTNewsMay 13 07:22 ET

Precision BioSciences | 10-Q: Quarterly report

SEC announcementMay 13 07:19 ET · Announcements

Express News | Precision BioSciences Inc - Expected Runway Into H2 2026

ReutersMay 13 07:08 ET

Precision BioSciences Q1 EPS $1.70 Beats $(1.91) Estimate, Sales $17.58M Beat $6.02M Estimate

Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $(1.91) by 189.01 percent. This is a 124.64 percent increase over losses

BenzingaMay 13 07:03 ET

Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, Vs. Street Est of $6.02M

07:02 AM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, vs. Street Est of $6.02M

MT NewswiresMay 13 07:02 ET

Express News | Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

ReutersMay 13 07:00 ET

Precision Biosciences 1Q Rev $17.6M >DTIL

Precision Biosciences 1Q Rev $17.6M >DTIL

Dow JonesMay 13 07:00 ET

Stocks Poised for Lower Open

Stocks are poised to open lower in New York on Monday as investors await a key inflation reading later in the week and ahead of earnings reports from major retailers.

Barron'sMay 12 18:35 ET

Express News | Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement

BenzingaMay 8 08:18 ET

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in A...

Stockhouse May 8 08:15 ET